The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation

Bone Marrow Transplantation

Volumn 46, Issue 10, 2011, Pages 1296-1302

  Al Ali, H K ^a   Bourgeois, M ^a   Krahl, R ^a   Edel, E ^a   Leiblein, S ^a   Poenisch, W ^a   Basara, N ^a   Lange, T ^a   Niederwieser, D ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

allogeneic HCT; elderly; graft; NK cells; stem cell donor

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; POTASSIUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APHERESIS; ARTICLE; BLOOD DONOR; BONE PAIN; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LEUKEMIA; CONTROLLED STUDY; DONOR AGE; DONOR SAFETY; ENGRAFTMENT; FEMALE; GRAFT RECIPIENT; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; HUMAN CELL; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SAFETY; SIBLING; SKIN DISEASE; STEM CELL MOBILIZATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHIMERISM; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 80053959213     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.310     Document Type: Article

References (33)

1. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275-291.
2. Reddy RL. Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfus Apher Sci 2005; 32: 63-72. (Pubitemid 40297898)
3. Hölig K, Kramer M, Kroschinsky F, Bornhäuser M, Mengling T, Schmidt AH et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3721-3722.
4. Martino M, Console G, Dattola A, Callea I, Messina G, Moscato T et al. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Bone Marrow Transplant 2009; 44: 163-168.
5. Halter J, Kodera Y, Ispizua AU, Greinix H, Schmitz H, Favre G et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94-101.
6. Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Gxroup for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702-3709. (Pubitemid 30412840)
7. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Socié té Française de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546. (Pubitemid 30078535)
8. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181. (Pubitemid 32064138)
9. Couban S, Barnett M. The source of cells for allografting. Biol Blood Marrow Transplant. 2003; 9: 669-673. (Pubitemid 38145749)
10. Gorin NC, Labopin M, Rocha V, Arcese W, Beksac M, Gluckman E et al. Marrow versus peripheral blood for genoidentical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood 2003; 102: 3043-3051. (Pubitemid 37248882)
11. Gallardo D, de la Cámara R, Nieto JB, Espigado I, Iriondo A, Jiménez-Velasco A et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica 2009; 94: 1282-1288.
12. Siddiq S, Pamphilon D, Brunskill S, Doree C, Hyde C, Stanworth S. Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev 2009; 1: CD006406.
13. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D. for the Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT (JACIE). The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant 2008; 41: 687-705. (Pubitemid 351587034)
14. Kreissig C, Kirsch A, Serke S. Characterization and measurement of CD34 expressing hematopoietic cells. J Chemother 1994; 3: 263-289. (Pubitemid 26038657)
15. Bryant E, Martin PJ. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation, 2nd edn. Blackwell Science: Boston, 1999, pp 197-206.
16. Tempescul A, Ianotto JC, Hardy E, Quivoron F, Petrov L, Berthou C. Peripheral blood stem cell collection in elderly patients. Ann Hematol. 2010; 89: 317-321.
17. Basara N, Schmetzer B, Blau IW, Bischoff M, Guenzelmann S, Kirsten D et al. Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study. Bone Marrow Transplant 2000; 25: 371-376. (Pubitemid 30114030)
18. Inoue H, Yasuda Y, Hattori K, Shimizu T, Matsumoto M, Yabe M et al. The kinetics of immune reconstitution after cord blood transplantation and selected CD34 stem cell transplantation in children: comparison with bone marrow transplantation. Int J Hematol. 2003; 77: 399-407.
19. Small TN, Avigan D, Dupont B, Smith K, Black P, Heller G et al. Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant 1997; 3: 65-67.
20. Small TN, Papadopoulos EB, Boulad F, Black P, Castro-Malaspina H, Childs BH et al. Comparison of immune reconstitution after unrelated and related T-cell depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 93: 467-480. (Pubitemid 29035728)
21. Ruggeri L, CapanniM,CasucciM,Volpi I, TostiA, Perruccio K et al. Role of natural killer cell alloreactivity in HLAmismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339. (Pubitemid 29300166)
22. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100. (Pubitemid 34229476)
23. Tanaka J, Tutumi Y, Mori A, Ohta S, Kobayashi S, Asaka M et al. Sequential analysis of HLA-C specific killer cell inhibitory receptor (CD158b) expressing peripheral blood mononuclear cells during chronic graft-versus-host disease. Bone Marrow Transplant 2000; 26: 287-90. (Pubitemid 30614408)
24. Tanaka J, Mori A, Ohta S, Yamamoto Y, Kobayashi S, Hashino S et al. Expression of HLA-C-specific natural killer cell receptors (CD158a and CD158b) on peripheral blood mononuclear cells after allogeneic bone marrow transplantation. Br J Haematol 2000; 108: 778-783. (Pubitemid 30304510)
25. Bornhauser M, Thiede C, Brendel C, Geissler G, Oelschlaegel U, Neubauer A et al. Stable engraftment after megadose blood stem cell transplantation across the HLA barrier: the case for natural killer cells as graft-facilitating cells. Transplantation 1999; 68: 87-88. (Pubitemid 29352836)
26. Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998; 101: 1835-1842. (Pubitemid 28226101)
27. Zeis M, Uharek L, Glass B, Gaska T, Steinmann J, Gassmann W et al. Allogeneic NK cells as potent anti-leukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1995; 59: 1734-1736.
28. Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990; 7: 2250-2262. (Pubitemid 20181179)
29. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110: 433-440. (Pubitemid 47026866)
30. Hsu KC, Keever-Taylor KA, Wilton A, Pinto C, Heller G, Arkun K et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884. (Pubitemid 40807317)
31. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008; 111: 1767-1772. (Pubitemid 351451480)
32. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642-650. (Pubitemid 44674074)
33. Samson D, Slaper-Cortenbach I, Pamphilon D, McGrath E, McDonald F, Urbano Ispizua A. Current status of JACIE accreditation in Europe: a special report from the Joint Accreditation Committee of the ISCT and the EBMT (JACIE). Bone Marrow Transplant 2007; 39: 133-141. (Pubitemid 46178747)